Table 1.

Numbers of persons, person-years of follow-up and cases/deaths for key leukaemia categories.

Class	Category	Person-years	Persons first at riska	Myeloid malignant neoplasms	AML	AML + MDS	CML	ALL	Acute leukaemia	Leukaemia excluding CLL, unclassified as AML/CML/ALL	Leukaemia excluding CLL
Total		7,641,362	310,905	274	140	158	61	71	243	93	365
Sex	Male	3,332,630	154,647	146	73	83	34	36	123	53	196
	Female	4,306,530	156,036	128	67	75	27	34	119	40	168
	Unknown	2204	222	0	0	0	0	1	1	0	1
Entry year	<1920	56	2	0	0	0	0	0	0	0	0
	1920–1929	37,505	576	2	1	1	1	0	3	2	4
	1930–1939	170,704	4115	11	1	1	3	0	1	10	14
	1940–1949	170,857	4638	3	0	0	2	1	2	12	15
	1950–1959	5,077,780	118,126	205	117	124	47	43	184	55	262
	1960–1969	300,211	6372	4	2	3	1	0	2	4	7
	1970–1979	263,511	9307	5	2	4	0	1	7	6	9
	1980–1989	50,382	2701	1	1	1	0	2	3	0	3
	1990–1999	1,056,900	84,058	32	10	17	6	16	26	2	34
	≥2000	513,463	81,010	11	6	7	1	8	15	2	17
Age at entry (years)a	0–4	1,427,710	56,366	34	17	23	6	17	42	12	52
	5–9	1,905,370	60,555	64	34	38	11	25	63	14	84
	10–14	1,519,830	58,714	58	28	33	17	9	45	14	68
	15–19	1,177,090	62,903	52	29	30	12	5	36	10	56
	20–29	1,343,570	61,245	51	29	30	12	14	49	19	74
	30–39	191,916	6497	5	2	2	1	1	6	10	14
	40–49	51,260	2357	6	1	2	1	0	2	8	10
	≥50	24,614	2268	4	0	0	1	0	0	6	7
Years since first exposurea	<0 or NA	1,667,610	50,335	68	27	31	16	10	44	41	94
	0–0.99	23,335	19,912	1	1	1	0	0	1	0	1
	1–1.99	25,243	2208	0	0	0	0	0	0	0	0
	2–4.99	568,364	167,316	10	5	7	2	10	19	6	23
	5–9.99	1,052,290	56,331	29	14	15	8	19	36	5	46
	10–14.99	745,666	7630	24	9	13	4	9	21	7	29
	15–19.99	529,238	2890	14	9	10	3	5	15	3	20
	20–29.99	865,351	2537	21	12	12	8	6	23	6	32
	≥30	2,164,270	1746	107	63	69	20	12	84	25	120
Attained age (years)a	0–4.99	124,753	56,366	1	1	1	0	4	6	1	6
	5–9.99	411,538	60,555	5	4	5	0	13	20	5	22
	10–14.99	623,591	58,714	12	5	6	5	11	18	2	23
	15–19.99	778,480	62,903	23	10	12	5	5	20	7	27
	20–29.99	1,731,430	61,245	36	19	23	9	12	39	12	52
	30–39.99	1,281,480	6497	28	14	14	9	6	20	7	36
	40–49.99	1,152,100	2357	42	21	22	12	6	33	12	51
	≥50	1,537,990	2268	127	66	75	21	14	87	47	148
Mean cumulative active bone marrow dose (Gy)	0	2,832,010	93,729	106	51	55	26	13	76	53	143
	0–0.004	964,831	65,125	24	10	10	6	1	14	5	22
	0.005–0.099	628,876	50,911	14	5	7	5	6	13	5	21
	0.010–0.019	669,905	48,357	11	6	8	1	15	22	3	25
	0.020–0.049	534,468	21,414	24	15	19	3	8	24	3	29
	0.050–0.099	425,622	10,015	16	12	12	2	4	19	4	22
	0.100–0.149	244,034	4946	12	5	5	3	2	9	5	15
	0.150–0.199	127,858	2761	9	6	8	0	1	8	2	9
	0.200–0.299	191,887	3918	3	0	0	3	1	2	2	6
	0.300–0.499	347,124	4788	9	3	4	2	4	7	2	11
	0.500–0.749	365,219	2206	16	8	10	3	5	14	3	19
	0.750–0.999	186,260	1211	8	4	4	2	2	10	4	12
	1.000–1.499	74,472	754	6	5	5	1	3	9	1	10
	1.500–1.999	29,564	326	8	6	7	0	0	6	1	7
	2.000–2.499	8232	178	4	2	2	2	0	2	0	4
	2.500–2.999	5708	158	2	1	1	1	4	5	0	6
	3.000–4.999	5241	107	2	1	1	1	2	3	0	4
	5.000–7.499	53	1	0	0	0	0	0	0	0	0

AML acute myeloid leukaemia, CML chronic myeloid leukaemia, ALL acute lymphoblastic leukaemia.

^aThe number of persons represents those first entering follow-up in the given categories (of attained age, time since first exposure etc.).